We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

164 hedge funds and large institutions have $6.54B invested in Ascendis Pharma A/S in 2023 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 58 increasing their positions, 65 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

413% more call options, than puts

Call options by funds: $117M | Put options by funds: $22.8M

8.86% less ownership

Funds ownership: 115.61% → 106.75% (-8.9%)

11% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 65

12% less funds holding

Funds holding: 187 → 164 (-23)

19% less capital invested

Capital invested by funds: $8.05B → $6.54B (-$1.51B)

35% less funds holding in top 10

Funds holding in top 10: 20 → 13 (-7)

57% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 37

Holders
164
Holders Change
-23
Holders Change %
-12.3%
% of All Funds
2.61%
Holding in Top 10
13
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-35%
% of All Funds
0.21%
New
16
Increased
58
Reduced
65
Closed
37
Calls
$117M
Puts
$22.8M
Net Calls
+$94.2M
Net Calls Change
+$7.85M

Top Buyers

1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$73.8M
2
Capital International Investors
Capital International Investors
California
+$48.2M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$45.3M
4
ACA
Avoro Capital Advisors
New York
+$25.7M
5
WP
Woodline Partners
California
+$24M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$605M
2
DTC
Deep Track Capital
Connecticut
-$85.5M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$38.9M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$16M
5
Citadel Advisors
Citadel Advisors
Florida
-$15.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$746M – – –
Artisan Partners
2
Artisan Partners
Wisconsin
$734M -$8.65M -75,615 -1%
Fidelity Investments
3
Fidelity Investments
Massachusetts
$552M -$8.8M -76,905 -1%
Janus Henderson Group
4
Janus Henderson Group
United Kingdom
$379M -$12.7M -111,125 -3%
T. Rowe Price Investment Management
5
T. Rowe Price Investment Management
Maryland
$372M +$73.8M +645,199 +23%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$361M -$38.9M -339,898 -9%
ACA
7
Avoro Capital Advisors
New York
$357M +$25.7M +225,000 +7%
Westfield Capital Management
8
Westfield Capital Management
Massachusetts
$337M -$1.38M -12,042 -0.4%
Wellington Management Group
9
Wellington Management Group
Massachusetts
$315M -$13.7M -119,813 -4%
Goldman Sachs
10
Goldman Sachs
New York
$273M +$3.28M +28,633 +1%
Capital International Investors
11
Capital International Investors
California
$213M +$48.2M +421,109 +27%
Massachusetts Financial Services
12
Massachusetts Financial Services
Massachusetts
$146M +$1.6M +13,972 +1%
Franklin Resources
13
Franklin Resources
California
$144M -$3.62M -31,618 -2%
TCM
14
TimesSquare Capital Management
New York
$91.4M +$6.96M +60,835 +8%
EAM
15
Eventide Asset Management
Massachusetts
$83.9M +$15K +131 +0%
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$82.7M +$45.3M +396,400 +106%
SI
17
Sofinnova Investments
California
$80.8M -$14.5M -126,768 -14%
PI
18
Putnam Investments
Massachusetts
$79.4M +$3.94M +34,453 +5%
SCM
19
Spyglass Capital Management
California
$76.6M -$56.6K -495 -0.1%
Invesco
20
Invesco
Georgia
$69.3M -$1.63M -14,226 -2%
AllianceBernstein
21
AllianceBernstein
Tennessee
$55.2M +$2.87M +25,112 +5%
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$53.6M -$16M -140,000 -22%
SEI Investments
23
SEI Investments
Pennsylvania
$51M +$4.44M +38,770 +9%
Brown Advisory
24
Brown Advisory
Maryland
$50M +$2.98M +26,080 +6%
RSCM
25
Rock Springs Capital Management
Maryland
$45.6M – – –
1
2 3 4 5

ASND Hedge Fund Activity: Q1 2023 in Review

164 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2023, worth a combined $6.54B — down 19% from $8.05B a quarter earlier.

Sellers outnumbered buyers: 37 funds closed out of ASND and 16 opened new positions — a net loss of 21 holders — while 65 trimmed existing stakes and 58 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $73.8M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $605M sold.

  • 164 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2023, down from 187 in Q4 2022.
  • Funds reported $6.54B of Ascendis Pharma A/S stock for Q1 2023, down 19% quarter-over-quarter.
  • 16 funds opened new Ascendis Pharma A/S positions in Q1 2023 and 37 closed out, a net change of -21 holders.
  • The largest Ascendis Pharma A/S buyer in Q1 2023 was T. Rowe Price Investment Management, an estimated $73.8M added.
  • The largest Ascendis Pharma A/S seller in Q1 2023 was Baker Bros. Advisors, an estimated $605M sold.

Based on aggregated 13F filings for Q1 2023.